News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: revenue_monster post# 113380

Saturday, 02/23/2013 10:20:59 AM

Saturday, February 23, 2013 10:20:59 AM

Post# of 347009
RM... I would have to disagree...the building is not on fire

"If they are looking for VC investment that would mean partner discussions aren't as mature as they would lead us to believe"



Partnering discussions vs. Institutional Ownership I believe are the two separate issues..... I believe Peregrine is trying to balance the act of presenting all their updates results (including trying to explain the Fargo Fiasco) to the investment community ( meetings in NY/Boston/upcoming Cowen/Roth) as well as to the BP's because I the only ones who should get a bad feeling are those competing BP's that will decline in sales revenue if Bavi enters the market and we do know this fact:

"The conservative approach we took following our internal review of data from this trial combines one of our bavituximab treatment arms with the placebo group with the resulting data remaining compelling to advance the program into Phase III development in second line NSCLC. We remain confident that the trial has demonstrated the potential of bavituximab in this difficult to treat disease," said Steven W. King, president and chief executive officer of Peregrine. "While our clinical, regulatory and manufacturing teams work together to prepare for an end-of-Phase II meeting with the FDA, we are continuing to update potential partners on these trial results and our future plans for advancing the program. Partnering interest remains high and the updates from this trial should help advance these discussions. We would like to express our gratitude to the patients who participated in the trial and look forward to continuing to develop potential treatments for cancer."



http://ih.advfn.com/p.php?pid=nmona&article=56360574

The building is not on fire.... its just all the noise from those standing in the corner making little subtle hints.... suggesting.... inferring that there is trouble ahead.

GLTA!

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y